MD Anderson, Astellas Pharma Sign Option Agreement

The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc. have signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news